[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100472762":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":18,"armGroups":25,"interventions":32,"overallOfficials":38,"centralContacts":42,"locations":47,"responsibleParty":64,"collaborators":18,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":18,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":18,"studyType":78,"phases":79,"briefSummary":80,"conditions":81,"keywords":18,"overallStatus":50,"whyStopped":18,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Standardized Uptake Value (SUV) of 68Ga-NC-BCH","SUV is a semiquantitative index commonly used in PET to quantify tissue metabolic activity, calculated as the ratio of the radioactivity concentration in the tissue of interest to the injected dose normalized by body weight. Bio-distribution of the tracer will be assessed by measuring the Standardized Uptake Value (SUV) in normal organs (e.g., liver, spleen, kidney) via PET\u002FCT imaging at specified time points post-injection.","2 years",[14],{"measure":15,"description":16,"timeFrame":17},"Diagnostic performance","To evaluate the diagnostic permormance of 68Ga-NC-BCH PET\u002FCT in identifying CLDN18.2-positive lesions, using immunohistochemistry (IHC)as the reference standard. The diagnostic performance will be assessed by receiver operating characteristic (ROC) curve analysis, with calculation of the area under the curve (AUC).","4 years",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"NA","SINGLE_GROUP","SCREENING",{"masking":24,"maskingDescription":18,"whoMasked":18},"NONE",[26],{"label":27,"type":28,"description":29,"interventionNames":30},"68Ga-NC-BCH","EXPERIMENTAL","Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-NC-BCH PET\u002FCT scan.",[31],"Drug: 18F-FDG",[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":18},"DRUG","18F-FDG","All study participants will undergo one 18F-FDG PET\u002FCT scan.",[27],[39],{"name":40,"affiliation":5,"role":41},"Hua Zhu","PRINCIPAL_INVESTIGATOR",[43],{"name":40,"role":44,"phone":45,"phoneExt":18,"email":46},"CONTACT","010-88196495","zhuhuabch@pku.edu.cn",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Beijing cancer hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":57,"coordinates":58},"Point",[59,60],116.39723,39.9075,{"lat":60,"lon":59},[63],{"name":40,"role":44,"phone":45,"phoneExt":18,"email":46},{"type":41,"investigatorFullName":40,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Associate Professor","100472762","cldn182-targeting-nanobody-probe-for-pet-imaging-in-solid-tumors-100472762",false,"NCT05436093","CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors","Inclusion Criteria:\n\n* 1\\. Aged \\>18 years old; ECOG 0 or 1;\n* 2\\. Patients with solid tumors;\n* 3\\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);\n* 4\\. life expectancy \\>=12 weeks.\n\nExclusion Criteria:\n\n* 1\\. Significant hepatic or renal dysfunction;\n* 2\\. Is pregnant or ready to pregnant;\n* 3\\. Cannot keep their states for half an hour;\n* 4\\. Refusal to join the clinical study;\n* 5\\. Suffering from claustrophobia or other mental diseases;\n* 6\\. Any other situation that researchers think it is not suitable to participate in the experiment.","ALL","18 Years","75 Years",{"count":76,"type":77},50,"ESTIMATED","INTERVENTIONAL",[20],"The objective of the study is to construct a noninvasive approach 68Ga-NC-BCH PET\u002FCT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.",[82],"Solid Tumor","2026-08-21",{"date":85,"type":86},"2026-08-26","ACTUAL",{"date":88,"type":86},"2022-06-23",{"date":90,"type":77},"2027-12",{"name":5,"class":6},1]